EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies ), 2013. Scientific Opinion on the substantiation of a health claim related to Yestimun ® and defence against pathogens in the upper respiratory tract pursuant to Article 13(5) of R egulation (EC) No 1924/2006

EFSA Publication; Inge Tetens

doi:10.2903/j.efsa.2013.3159

EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies ), 2013. Scientific Opinion on the substantiation of a health claim related to Yestimun ® and defence against pathogens in the upper respiratory tract pursuant to Article 13(5) of R egulation (EC) No 1924/2006

EFSA Publication, Inge Tetens

6 Citationer (Scopus)

Abstract

Following an application from Leiber GmbH, submitted for authorisation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of Germany, the Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the scientific substantiation of a health claim related to Yestimun® and defence against pathogens in the upper respiratory tract. The food that is the subject of the health claim, Yestimun®, which consists of (1,3)-(1,6)-β-D-glucans from brewer’s yeast cell wall, is sufficiently characterised. The claimed effect, defence against pathogens in the upper respiratory tract, is a beneficial physiological effect. No human intervention studies from which conclusions could be drawn for the scientific substantiation of the claim were provided by the applicant. The Panel concludes that a cause and effect relationship has not been established between the consumption of Yestimun® ((1,3)-(1,6)-β-D-glucans from brewer’s yeast cell wall) and defence against pathogens in the upper respiratory tract.
© European Food Safety Authority, 2013

Originalsprog	Engelsk

Forlag	European Food Safety Authority
DOI	https://doi.org/10.2903/j.efsa.2013.3159
Status	Udgivet - 2013
Udgivet eksternt	Ja

Emneord

Yestimun®
beta-glucans
Brewer’s yeast
Pathogens
Upper respiratory tract
Health claims

Adgang til dokumentet

10.2903/j.efsa.2013.3159

Citationsformater

Publication, EFSA., & Tetens, I. (2013). EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies ), 2013. Scientific Opinion on the substantiation of a health claim related to Yestimun ® and defence against pathogens in the upper respiratory tract pursuant to Article 13(5) of R egulation (EC) No 1924/2006. European Food Safety Authority. https://doi.org/10.2903/j.efsa.2013.3159

EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies ), 2013. Scientific Opinion on the substantiation of a health claim related to Yestimun ® and defence against pathogens in the upper respiratory tract pursuant to Article 13(5) of R egulation (EC) No 1924/2006. / Publication, EFSA; Tetens, Inge.

European Food Safety Authority, 2013.

Publikation: Bog/antologi/afhandling/rapport › Rapport › Forskning › peer review

Publication, EFSA & Tetens, I 2013, EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies ), 2013. Scientific Opinion on the substantiation of a health claim related to Yestimun ® and defence against pathogens in the upper respiratory tract pursuant to Article 13(5) of R egulation (EC) No 1924/2006. European Food Safety Authority. https://doi.org/10.2903/j.efsa.2013.3159

Publication EFSA, Tetens I. EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies ), 2013. Scientific Opinion on the substantiation of a health claim related to Yestimun ® and defence against pathogens in the upper respiratory tract pursuant to Article 13(5) of R egulation (EC) No 1924/2006. European Food Safety Authority, 2013. doi: 10.2903/j.efsa.2013.3159

@book{bded5deede694b4dbbd994b0c9024224,

title = "EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies ), 2013. Scientific Opinion on the substantiation of a health claim related to Yestimun {\textregistered} and defence against pathogens in the upper respiratory tract pursuant to Article 13(5) of R egulation (EC) No 1924/2006",

abstract = "Following an application from Leiber GmbH, submitted for authorisation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of Germany, the Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the scientific substantiation of a health claim related to Yestimun{\textregistered} and defence against pathogens in the upper respiratory tract. The food that is the subject of the health claim, Yestimun{\textregistered}, which consists of (1,3)-(1,6)-β-D-glucans from brewer{\textquoteright}s yeast cell wall, is sufficiently characterised. The claimed effect, defence against pathogens in the upper respiratory tract, is a beneficial physiological effect. No human intervention studies from which conclusions could be drawn for the scientific substantiation of the claim were provided by the applicant. The Panel concludes that a cause and effect relationship has not been established between the consumption of Yestimun{\textregistered} ((1,3)-(1,6)-β-D-glucans from brewer{\textquoteright}s yeast cell wall) and defence against pathogens in the upper respiratory tract.{\textcopyright} European Food Safety Authority, 2013",

keywords = "Yestimun{\textregistered}, beta-glucans, Brewer{\textquoteright}s yeast, Pathogens, Upper respiratory tract, Health claims",

author = "EFSA Publication and Inge Tetens",

year = "2013",

doi = "10.2903/j.efsa.2013.3159",

language = "English",

publisher = "European Food Safety Authority",

}

TY - RPRT

T1 - EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies ), 2013. Scientific Opinion on the substantiation of a health claim related to Yestimun ® and defence against pathogens in the upper respiratory tract pursuant to Article 13(5) of R egulation (EC) No 1924/2006

AU - Publication, EFSA

AU - Tetens, Inge

PY - 2013

Y1 - 2013

N2 - Following an application from Leiber GmbH, submitted for authorisation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of Germany, the Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the scientific substantiation of a health claim related to Yestimun® and defence against pathogens in the upper respiratory tract. The food that is the subject of the health claim, Yestimun®, which consists of (1,3)-(1,6)-β-D-glucans from brewer’s yeast cell wall, is sufficiently characterised. The claimed effect, defence against pathogens in the upper respiratory tract, is a beneficial physiological effect. No human intervention studies from which conclusions could be drawn for the scientific substantiation of the claim were provided by the applicant. The Panel concludes that a cause and effect relationship has not been established between the consumption of Yestimun® ((1,3)-(1,6)-β-D-glucans from brewer’s yeast cell wall) and defence against pathogens in the upper respiratory tract.© European Food Safety Authority, 2013

AB - Following an application from Leiber GmbH, submitted for authorisation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of Germany, the Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the scientific substantiation of a health claim related to Yestimun® and defence against pathogens in the upper respiratory tract. The food that is the subject of the health claim, Yestimun®, which consists of (1,3)-(1,6)-β-D-glucans from brewer’s yeast cell wall, is sufficiently characterised. The claimed effect, defence against pathogens in the upper respiratory tract, is a beneficial physiological effect. No human intervention studies from which conclusions could be drawn for the scientific substantiation of the claim were provided by the applicant. The Panel concludes that a cause and effect relationship has not been established between the consumption of Yestimun® ((1,3)-(1,6)-β-D-glucans from brewer’s yeast cell wall) and defence against pathogens in the upper respiratory tract.© European Food Safety Authority, 2013

KW - Yestimun®

KW - beta-glucans

KW - Brewer’s yeast

KW - Pathogens

KW - Upper respiratory tract

KW - Health claims

U2 - 10.2903/j.efsa.2013.3159

DO - 10.2903/j.efsa.2013.3159

M3 - Report

BT - EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies ), 2013. Scientific Opinion on the substantiation of a health claim related to Yestimun ® and defence against pathogens in the upper respiratory tract pursuant to Article 13(5) of R egulation (EC) No 1924/2006

PB - European Food Safety Authority

ER -